Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vedolizumab

vedolizumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of vedolizumab

23 trials tracked of vedolizumab: 14 in phase 3 or 4 and 10 with published results. The most-cited published study has 721 citations.

23Trials tracked
14Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 4 Phase 3 10 Phase 2 5 Phase 1 3 Other / NA 1
  1. Phase 3 An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis Completed · 721 cited
  2. Phase 3 Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease Completed · 209 cited
  3. Phase 3 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease Completed · 190 cited
  4. Phase 4 A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis Completed · 111 cited
  5. Phase 3 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis Completed · 99 cited
  6. Phase 4 Triple Combination Therapy in High Risk Crohn's Disease (CD) Completed · 87 cited
Show 17 more trials
  1. Phase 4 Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease Completed · 80 cited
  2. Phase 3 Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation Completed · 50 cited
  3. Phase 3 Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease Completed · 25 cited
  4. Phase 4 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed · 11 cited
  5. Phase 3 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) Completed
  6. Phase 3 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease Completed
  7. Phase 3 Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease Completed
  8. Phase 3 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis Completed
  9. Phase 2 Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease Completed
  10. Phase 2 Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis Completed
  11. Phase 2 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) Completed
  12. Phase 2 Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) Completed
  13. Phase 2 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) Completed
  14. Phase 1 A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants Completed
  15. Phase 1 Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab Completed
  16. Phase 1 Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT Completed
  17. N/A Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis] Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review
Allergy & Immunology Sys. Review
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review Why Hives Return to Old Injection Spots
This case report and literature review describes the first documented instance of vedolizumab-associated recall urticaria in a 25-year-old m…
A new case report reveals a rare skin reaction where hives return strictly to past injection sites.
Frontiers Apr 21, 2026
Vedolizumab plus curcumin improves remission in moderate-to-severe ulcerative colitis versus vedolizumab alone
Rheumatology RCT
Vedolizumab plus curcumin improves remission in moderate-to-severe ulcerative colitis versus vedolizumab alone Could adding curcumin to your current ulcerative colitis treatment help you reach remission faster?
This multicenter, double-blind randomized controlled trial enrolled 159 patients with moderate-to-severe ulcerative colitis.
Adding curcumin to ulcerative colitis treatment helped more patients reach symptom remission faster than using standard drugs alone.
Frontiers Apr 8, 2026
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Gastroenterology Phase IV
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…
CT.gov Mar 27, 2026